Page 34 - GPD-3-2

Gene & Protein in Disease Review of CAR-T in ADs

pemphigus foliaceus: An overview of the clinical from multiple sclerosis. Lancet. 2004;364(9451):2106-2112.
presentation, investigations and management. Clin Exp doi: 10.1016/s0140-6736(04)17551-x
Dermatol. 2019;44(7):740-746.
61. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ,
doi: 10.1111/ced.14041 Weinshenker BG. The spectrum of neuromyelitis optica.
50. Kridin K. Pemphigus group: Overview, epidemiology, mortality, Lancet Neurol. 2007;6(9):805-815.
and comorbidities. Immunol Res. 2018;66(2):255-270.
doi: 10.1016/s1474-4422(07)70216-8
doi: 10.1007/s12026-018-8986-7
62. Wingerchuk DM, Banwell B, Bennett JL, et al. International
51. Malik AM, Tupchong S, Huang S, Are A, Hsu S, consensus diagnostic criteria for neuromyelitis optica
Motaparthi K. An updated review of pemphigus diseases. spectrum disorders. Neurology. 2015;85(2):177-189.
Medicina (Kaunas). 2021;57(10):1080.
doi: 10.1212/wnl.0000000000001729
doi: 10.3390/medicina57101080 63. Derdelinckx J, Reynders T, Wens I, Cools N, Willekens B.
52. Ellebrecht CT, Bhoj VG, Nace A, et al. Reengineering Cells to the rescue: Emerging cell-based treatment
chimeric antigen receptor T cells for targeted therapy of approaches for NMOSD and MOGAD. Int J Mol Sci.
autoimmune disease. Science. 2016;353(6295):179-184. 2021;22(15):177-189.
doi: 10.1126/science.aaf6756 doi: 10.3390/ijms22157925
53. Lee J, Lundgren DK, Mao X, et al. Antigen-specific B cell 64. Qin C, Tian DS, Zhou LQ, et al. Anti-BCMA CAR T-cell
depletion for precision therapy of mucosal pemphigus therapy CT103A in relapsed or refractory AQP4-IgG
vulgaris. J Clin Invest. 2020;130(12):6317-6324. seropositive neuromyelitis optica spectrum disorders:
Phase 1 trial interim results. Signal Transduct Target Ther.
doi: 10.1172/jci138416
2023;8(1):5.
54. Mantegazza R, Bernasconi P, Cavalcante P. Myasthenia
gravis: From autoantibodies to therapy. Curr Opin Neurol. doi: 10.1038/s41392-022-01278-3
2018;31(5):517-525. 65. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP
antibodies: The past, the present and the future. Nat Rev
doi: 10.1097/wco.0000000000000596
Rheumatol. 2011;7(7):391-398.
55. Hehir MK, Silvestri NJ. Generalized myasthenia gravis: doi: 10.1038/nrrheum.2011.76
Classification, clinical presentation, natural history, and
epidemiology. Neurol Clin. 2018;36(2):253-260. 66. Sakkas LI, Bogdanos DP, Katsiari C, Platsoucas CD. Anti-
citrullinated peptides as autoantigens in rheumatoid
doi: 10.1016/j.ncl.2018.01.002
arthritis-relevance to treatment. Autoimmun Rev.
56. Granit V, Benatar M, Kurtoglu M, et al. Safety and clinical 2014;13(11):1114-1120.
activity of autologous RNA chimeric antigen receptor T-cell
therapy in myasthenia gravis (MG-001): A prospective, doi: 10.1016/j.autrev.2014.08.012
multicentre, open-label, non-randomised phase 1b/2a study. 67. Cantaert T, Teitsma C, Tak PP, Baeten D. Presence and role
Lancet Neurol. 2023;22(7):578-590. of anti-citrullinated protein antibodies in experimental
arthritis models. Arthritis Rheum. 2013;65(4):939-948.
doi: 10.1016/s1474-4422(23)00194-1
doi: 10.1002/art.37839
57. O’Leary K. CAR T cell therapy for myasthenia gravis. Nat
Med. 2023. 68. Koivula MK, Heliövaara M, Ramberg J, et al. Autoantibodies
binding to citrullinated telopeptide of type II collagen and
doi: 10.1038/d41591-023-00062-2
to cyclic citrullinated peptides predict synergistically the
58. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for development of seropositive rheumatoid arthritis. Ann
the treatment of neuromyelitis optica spectrum disorder Rheum Dis. 2007;66(11):1450-1455.
(N-MOmentum): A double-blind, randomised placebo- doi: 10.1136/ard.2006.062919
controlled phase 2/3 trial. Lancet. 2019;394(10206):1352-1363.
69. Zhang B, Wang Y, Yuan Y, et al. In vitro elimination of
doi: 10.1016/s0140-6736(19)31817-3
autoreactive B cells from rheumatoid arthritis patients by
59. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. universal chimeric antigen receptor T cells. Ann Rheum Dis.
IgG marker of optic-spinal multiple sclerosis binds to the 2021;80(2):176-184.
aquaporin-4 water channel. J Exp Med. 2005;202(4):473-477.
doi: 10.1136/annrheumdis-2020-217844
doi: 10.1084/jem.20050304
70. Orvain C, Boulch M, Bousso P, Allanore Y, Avouac J. Is there
60. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum a place for chimeric antigen receptor-T cells in the treatment
autoantibody marker of neuromyelitis optica: Distinction of chronic autoimmune rheumatic diseases? Arthritis

Volume 3 Issue 2 (2024) 13 doi: 10.36922/gpd.2851